|
Tumor Genomic Pre-test Counseling Tool for Black or African-American Men With Prostate Cancer
RECRUITINGN/ASponsored by University of California, San Francisco
Actively Recruiting
PhaseN/A
SponsorUniversity of California, San Francisco
Started2023-12-01
Est. completion2027-05-31
Eligibility
Age18 Years+
SexMALE
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →
NCT06171139
Summary
The overall goal of the study is to improve equitable delivery of pre-Tumor genetic testing (TGT) counseling tool for Black or African American men with metastatic prostate cancer and evaluating the tool for implementation.
Eligibility
Age: 18 Years+Sex: MALEHealthy volunteers accepted
Inclusion Criteria: Stage 1: 1. Age 18-years-old or older 2. Identifies as Black or African American, by either chart documentation or participant self-report. Mixed-race including Black or African American is included. 3. Metastatic prostate cancer, by either chart documentation or participant self-report. Pathology report not needed. 4. Able to understand study procedures and to comply with them for the entire length of the study. 5. Able to understand a written information sheet and willing to verbally consent. 6. Fluent in English (reading, writing, and speaking) Stage 2: 1. Age 18-years-old or older 2. Identifies as Black or African-American, by either chart documentation or participant self-report. Mixed-race including Black or African-American is included. 3. Metastatic prostate cancer, by either chart documentation or participant self-report. Pathology report not needed. 4. Able to understand study procedures and to comply with them for the entire length of the study. 5. Fluent in English (reading, writing, and speaking). 6. Anticipated discussion of TGT within 0-90 days of enrollment, per treating oncology provider's discretion. TGT involves use of any cancer genetic sequencing (whether standard-of-care or part of a research protocol) via any one of the following: 1. Somatic DNA testing of already-collected tissue. 2. Somatic DNA testing of tissue to be collected in the future via biopsy, surgery, or other procedure. 3. Blood-based DNA testing to evaluate for circulating tumor DNA. 7. Able to understand a written informed consent document and willing to sign it. Exclusion Criteria: Contraindication to any study-related procedure or assessment in either stage.
Conditions3
CancerProstate CancerProstate Cancer Metastatic
Locations1 site
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhaseN/A
SponsorUniversity of California, San Francisco
Started2023-12-01
Est. completion2027-05-31
Eligibility
Age18 Years+
SexMALE
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →
NCT06171139